Ovid Therapeutics, an early stage biotech developing treatments for rare neurodevelopmental disorders, raised $75 million by offering 5 million shares at $15, the low end of the range of $15 to $17.
Ovid Therapeutics plans to list on the Nasdaq under the symbol OVID. Citi and Cowen & Company acted as lead managers on the deal.
